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Clinical Manifestations and Hematological Profiles of Pediatric Acute 
Myeloblastic Leukemia Patients:  3 Years Observational Study in A West 
Java Tertiary Hospital, Indonesia
Abstract  Objective: To determine and describe the clinical manifestations and 
hematological profiles of pediatric Acute Myeloblastic Leukemia (AML) in 
Dr. Hasan Sadikin General Hospital (RSHS), Bandung as a tertiary hospital in 
West Java, Indonesia.
 Methods: A retrospective cross-sectional study using the total sampling 
method was performed on the medical records of pediatric patients (0-18 
years old)who were diagnosed as AML for the first time through bone marrow 
examination during the period of January 1, 2015–December 31, 2017.
 
 Results: Of the 54 subjects who met the inclusion criteria, 42.6% were AML 
patients in the age group 6-12 years with male patients comprised 59.3% of 
the total number of subjects. Patients generally experienced pallor (83.3%), 
fever (75.9%), and decreased appetite (70.4%). The hematological profiles 
showed that 35.2% of patients had Hb <6.5 g/dL and 44.4% had a leukocyte 
count of  of >50,000 cells/mm3. The majority of the subjects had a platelet 
count of <50,000 cells/mm3 (83.3%) and almost half of them had a peripheral 
blasts count of >50% (46.3%).
 
 Conclusions: Clinical manifestations and hematological profiles are 
important to diagnose AML, especially in pediatric patients. By assessing the 
manifestations and profiles, it is feasible to access and detect suspected cases 
of AML.
                Keywords: Acute myeloblastic leukemia, clinical manifestation, 
hematological profile, pediatric
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Introduction
Acute Myeloblastic Leukemia (AML) is a type 
of acute leukemia  with  rapid and progressive 
infiltrations of myeloid/myeloblast cells to 
the bone marrow, blood, and other organs.1 In 
United States, 350 new cases of AML in pediatric 
are identified annuallya.2 Approximately 15–
20% of leukemia cases in children ≤15 years 
old are AML.2, 3 In Indonesia, acute leukemia is 
the most common type of cancer in children.4 
Data from a department of pediatrics in a 
tertiary hospital in Jakarta demonstrated that 
21.8% of acute leukemia in 2007-2010 are 
AML.5 Another study in a tertiary hospital in 
Yogyakarta also showed that 27.7% of acute 
leukemia are AML, which is higher than in 
western countries.6 
To be able to improve the survival rate 
of pediatric AML patients, it is necessary to 
understand the characteristics of clinical 
and hematological profiles of the patients to 
facilitate early diagnosis. Pediatric AML have 
various clinical manifestations, with anemia 
(pale, weak, decreased in appetite and body 
weight), bleeding, and infection as the most 
common. In addition, cancer cells can migrate 
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and cause manifestations in other organs such 
as in the liver, spleen, and lymph nodes.7, 8
Based on the hematological examination, 
AML patients generally experience anemia, 
leukocytosis, thrombocytopenia, and 
increased number of blast cells.9 A study in 
Dharmais Cancer Hospital Jakarta showed that 
83% of AML patients have a hemoglobin level 
of <12 g/dL, 61% have a leukocyte count of 
≥50,000 cells/mm3, and 57% have a platelet 
count of <30,000 cells/mm3.4 Data from a 
tertiary hospital in Jakarta (2007–2009) 
revealed that AML patients that male patients 
with hepatomegaly and a platelet count of 
<20,000 cells/mm3 tend to experience failure 
to achieve remission.5
 Reports on clinical and hematological 
profiles of pediatric AML patients in tertiary 
hospitals are still lacking. Therefore, this 
study aimed to gather information on clinical 
manifestations and hematological profiles of 
pediatric AML patients in a tertiary  hospital in 
West Java Province, Indonesia. 
Methods
This was a cross-sectional study on all 
inpatient medical records of AML pediatric 
patients treated in Dr. Hasan Sadikin General 
Hospital Bandung, West Java, Indonesia during 
the period of January 1, 2015 to December 31, 
2017 using the total sampling approach. The 
study was performed from June to July 2018 
The inclusion criteria of this study was all 
medical records of pediatric (0–18 years old) 
patients who were diagnosed as AML in Dr. 
Hasan Sadikin General Hospital (Rumah Sakit 
Hasan Sadikin, RSHS) for the first time based on 
the results of the bone marrow examination. 
Medical records were excluded if they were 
incomplete, lost, or contained inaccessible 
data. Medical records of patients  who who did 
not come to RSHS for the first time,  refused 
to undergo  bone marrow examination, and 
diagnosed as non-AML were also excluded.  
This study had been approved by the 
Research Ethical Committee of Universitas 
Padjadjaran, Bandung through issuance 
of the ethical clearance  Number 202/
UN6.KEP/EC/2018 and by the Medical 
Research Ethical Committee of Dr. Hasan 
Sadikin General Hospital, Bandung with 
the issuance of ethical clearance Number 
LB.02.01/X.2.2.1/9375/2018. This study 
was also acknowledged and approved by the 
Pediatrics Department and Clinical Pathology 
Department of Dr. Hasan Sadikin General 
Hospital Bandung, Indonesia.
Variables of this study were patient 
demographics (including age and sex), clinical 
manifestations of AML, and hematological 
profiles (hemoglobin level, leukocyte count, 
thrombocyte count and peripheral blast 
count). Hemoglobin level was categorized 
into <6.5, 6.5–7.9, 8.0–9.4, 9.5–10.9 and 
≥11 g/dL. Leukocyte count was classified 
into <10,000, 10,000–50,000, and >50,000 
cells/mm3. Platelet count was grouped into 
<50,000, 50,000-99,999, 100,000–149,999, 
150,000–450,000, and >450,000 cells/mm3 
while peripheral blast count was categorized 
into <20, 20–50, and >50%. 
Data were then selected and sorted based 
on the inclusion criteria and analyzed using 
descriptive statistics and processed using 
Microsoft® Excel 2016 and IBM® SPSS® 
version 20. Tables, percentages, and charts 
were used to present patient demographics, 
clinical manifestations, and hematological 
profiles. 
Results 
Of the seventy-three medical records retrieved, 
54 met the inclusion criteria of this study. The 
flow diagram used for the selection process is 
presented  in Figure 1.
The age and gender distribution of the AML 
pediatric patients in RSHS from 2015–2017 
were depicted in Figure 2. Most patients were 
in the age group 6–12 years old (42.6%) and 
males (59.3%).
Figure 3 displays the clinical manifestations 
of pediatric AML patients in RSHS during the 
period of 2015–2017. The most frequently 
observed clinical manifestations were pallor 
(83.3%), followed by fever (75.9%), loss of 
appetite (70.4%), as well as weight loss and 
hepatomegaly (each 59.3%).
Table 1 illustrates the hematological 
profiles of pediatric AML patients in RSHS. 
Most subjects had a hemoglobin level of <6.5 
g/dL (35.2%) whereas the leukocyte and 
platelet counts were mostly in the category 
of >50,000 cells/mm3 (44.4%) and <50,000 
cells/mm3 (83.3%), respectively. The number 
of blast cells on peripheral blood examination 
were mostly in the category >50% (46.3%).
Discussion
This study demonstrated that 42.6% of 
children with AML in RSHS from 2015-2017 
belonged to the age group 6–12 years old 
and most of the patients were males (59.3%). 
This finding is similar to the finding of a study 
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Figure 1 Flow Diagram for Medical Record Selection Process
Table 1 Hematological Profiles of Pediatric AML Patients
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Figure 3 Clinical Manifestations in Pediatric AML Patients
Figure 2 Age and Gender of Pediatric AML Patients
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by Supriyadi E et al. stating 41.4% of the 
pediatric AML patients were 6–12 years old 
when diagnosed.10 Another study conducted 
by Rahadiyanto et al.11 and Sjakti HA et al. also 
stated that AML in children is more frequent in 
males (52.4% and 61.3% respectively).5
Most of the pediatric AML patients 
had more than one clinical manifestation. 
Results showed that pallor was the clinical 
manifestation with the highest frequency that 
was seen in 83.3% of the patients, followed by 
fever (75.9%), decreased appetite (70.4%), as 
well as weight loss and hepatomegaly (each 
59.3%). These data resemble the results of a 
study by Hu et al.12 which concluded that the 
most common manifestations of pediatric AML 
patients are pallor (60.3%), fever (40.5%), 
and mucosal bleeding (15.5%). Another study 
from Asif and Hassan13 in Pakistan also stated 
that pallor is the most common manifestations 
(86.6%), followed by fever (82.9%) and 
bleeding (52.4%), while hepatomegaly is 
found in 38 of 82 patients (46.3%).
Hematopoietic disorders of AML cause 
several clinical manifestations such as 
symptoms of anemia (most commonly 
paleness, weakness, and decreased appetite), 
infection, and an increased probability to 
bleed.13 In AML, the cancer cells do not only 
accumulate in the bone marrow, but also in 
other organs, such as liver, spleen, lymph 
nodes, central nervous system, and skin, which 
were also identified in this study.14 
The hemoglobin level of this study was 
mostly found in the category of <6.5 g/dL 
(35.2%). This was in line with a study  by Chang 
et al.15 Most patients in were in the category of 
<8 g/dL (45.8% of 107).Similar findings are 
presented by Rahmadin  et al.8 who reported 
that 48.57% of AML patients had a hemoglobin 
level of <6 g/dL. Anemia is usually caused 
by inadequate hematopoiesis triggered by 
abundant proliferation of leukocytes in bone 
marrow.7,8
Most patients in this study had a leukocyte 
count in the category of >50,000 cells/mm3 
(44.4%). This is similar to the findings of 
Johnston et al.16 which revealed that 50.7% of 
their patients had 10,000-99,999 cells/mm3 
leukocytes.It is concluded that the majority 
of pediatric AML patients in this study 
experienced hyperleukocytosis caused by 
blocked leukocyte maturation leading to the 
accumulation of myeloid cells in bone marrow 
and vessels.7, 8
In this study, the platelet count was 
predominantly in the category of <50,000 cells/
mm3, which reflects severe thrombocytopenia 
(83.3%). This is supported by a finding 
from Mehta et al.17 stating that 88.9% of the 
patients have  thrombocytopenia (<150,000 
cells/mm3). Thrombocytopenia can be caused 
by bone marrow infiltration, disseminated 
intravascular coagulation, immunological 
reactions or secondary hypersplenism due to 
an enlarged spleen.18   
In  this study, 46.3% of the patients 
had >50% blast cells on peripheral blood 
examination, which is similar to a previous 
study by Rendra et al.19 with 41.02% of their 
patients had 50–59% blasts.This condition is 
a result of disturbed myeloid cell development 
that leads to blast accumulation in bone 
marrow and blood.8 The initial suspicion 
of AML may arise when the blasts count is 
>20% on bone marrow or peripheral blood 
examination, when bone marrow is not 
possible.7
This study also has limitations. One of them 
is the difficulty in reading and accessing patient 
medical records. In addition, researchers were 
not able to collect data other than those from 
2015 to 2017 due to limited time for data 
collection and incomplete medical records 
from before 2015.
It is recommended that this type of study is 
performed in a longer period of time and with 
a larger sample size or other variables that 
have not been studied yet. Subsequent studies 
can also explore the links between variables 
discovered in this study. 
In conclusion, clinical manifestations 
and hematological profiles are important 
for diagnosing AML, especially in pediatric 
patients, to make it feasible to detect AML 
cases earlier. 
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